Safety in numbers: risankizumab for moderate-to-severe psoriasis

被引：1
作者：
Mirali, S. [1 ]
Fabusiwa, K. [2 ]
Linos, E. [3 ]
机构：
[1] Univ Toronto, Fac Med, Toronto, ON, Canada
[2] Guys & St Thomas Hosp, London, England
[3] Stanford Univ, Dept Dermatol, Palo Alto, CA 94305 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 186卷 / 03期
关键词：
D O I：
10.1111/bjd.20947
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：394 / 395
页数：2
相关论文
共 9 条
  • [1] The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives
    Burden, A. D.
    Warren, R. B.
    Kleyn, C. E.
    McElhone, K.
    Smith, C. H.
    Reynolds, N. J.
    Ormerod, A. D.
    Griffiths, C. E. M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (03) : 545 - 554
  • [2] Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
    Feagan, Brian G.
    Sandborn, William J.
    D'Haens, Geert
    Panes, Julian
    Kaser, Arthur
    Ferrante, Marc
    Louis, Edouard
    Franchimont, Denis
    Dewit, Olivier
    Seidler, Ursula
    Kim, Kyung-Jo
    Neurath, Markus F.
    Schreiber, Stefan
    Scholl, Paul
    Pamulapati, Chandrasena
    Lalovic, Bojan
    Visvanathan, Sudha
    Padula, Steven J.
    Herichova, Ivona
    Soaita, Adina
    Hall, David B.
    Bocher, Wulf O.
    [J]. LANCET, 2017, 389 (10080) : 1699 - 1709
  • [3] Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
    Gordon, K. B.
    Lebwohl, M.
    Papp, K. A.
    Bachelez, H.
    Wu, J. J.
    Langley, R. G.
    Blauvelt, A.
    Kaplan, B.
    Shah, M.
    Zhao, Y.
    Sinvhal, R.
    Reich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 466 - 475
  • [4] Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
    Gordon, Kenneth B.
    Strober, Bruce
    Lebwohl, Mark
    Augustin, Matthias
    Blauvelt, Andrew
    Poulin, Yves
    Papp, Kim A.
    Sofen, Howard
    Puig, Lluis
    Foley, Peter
    Ohtsuki, Mamitaro
    Flack, Mary
    Geng, Ziqian
    Gu, Yihua
    Valdes, Joaquin M.
    Thompson, Elizabeth H. Z.
    Bachelez, Herve
    [J]. LANCET, 2018, 392 (10148) : 650 - 661
  • [5] Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
    Iskandar, I. Y. K.
    Ashcroft, D. M.
    Warren, R. B.
    Lunt, M.
    McElhone, K.
    Smith, C. H.
    Reynolds, N. J.
    Griffiths, C. E. M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : 1410 - 1421
  • [6] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16) : 1551 - 1560
  • [7] Out-of-Pocket Costs of Specialty Medications for Psoriasis and Psoriatic Arthritis Treatment in the Medicare Population
    Pourali, Sarah P.
    Nshuti, Leonce
    Dusetzina, Stacie B.
    [J]. JAMA DERMATOLOGY, 2021, 157 (10) : 1239 - 1241
  • [8] Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
    Reich, Kristian
    Gooderham, Melinda
    Thaci, Diamant
    Crowley, Jeffrey J.
    Ryan, Caitriona
    Krueger, James G.
    Tsai, Tsen-Fang
    Flack, Mary
    Gu, Yihua
    Williams, David A.
    Thompson, Elizabeth H. Z.
    Paul, Carle
    [J]. LANCET, 2019, 394 (10198) : 576 - 586
  • [9] Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial
    Warren, R. B.
    Blauvelt, A.
    Poulin, Y.
    Beeck, S.
    Kelly, M.
    Wu, T.
    Geng, Z.
    Paul, C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (01) : 50 - 59
1